Printer Friendly

DEPRENYL ANIMAL HEALTH, INC. REPORTS U.S. PATENT ALLOWANCE FOR USE OF ANIPRYL IN TREATMENT OF CANINE CUSHING'S DISEASE

DEPRENYL ANIMAL HEALTH, INC. REPORTS U.S. PATENT ALLOWANCE FOR USE
 OF ANIPRYL IN TREATMENT OF CANINE CUSHING'S DISEASE
 OVERLAND PARK, Kan., Sept. 3 /PRNewswire/ -- Deprenyl Animal Health, Inc. (NASDAQ: DAHI; TSE: DAH) reported today that the United States Patent and Trademark Office has issued to the company's a 'Notice of Allowance' for the use of 1-deprenyl (Anipryl/R/) for treatment of Cushing's Disease (also known as Pituitary Dependent Hyperadrenocorticism or PDH) in the dog.
 In making the announcement, Dr. David R. Stevens, president of Deprenyl Animal Health, said, "We are extremely pleased with the rapid approval of this patent application in just five months from submission. Importantly, the issuance of this patent is both a validation of the drug's potential attributes and commercial protection. It is also a major step forward in the company's comprehensive program to develop Anipryl as a pharmaceutical to enhance the health of aging pets."
 Dr. William Ruehl, scientific director of DAHI, stated, "The preliminary positive results that we have achieved in clinical cases in a pilot study at the Kansas State University School of Veterinary Medicine will soon be followed by an expanded clinical trial at a number of trial sites.
 Dr. Ruehl added, "Anipryl may represent a significant step forward in the treatment of Cushing's Disease. Currently, there is no FDA approved drug for canine Cushing's Disease, a progressive and uniformly fatal disorder affecting dogs."
 Cushing's is one of the most common endocrine disorders in dogs, affecting from 3 to 5 out of each 1,000 canine patients seen at American veterinary medical school clinics each year, representing a potential market in the U.S.A. pet dog population of perhaps 50,000 cases, annually. The clinical program indicates that some dogs are responding well to Anipryl treatment and exhibited normalization of certain key laboratory test results and/or mitigation of clinical signs. "These animals will require treatment for the remainder of their lives," Dr. Ruehl stated.
 DAHI was established in 1991 to develop for the U.S.A. and Canadian markets animal health applications for the pharmaceutical 1-deprenyl. The company is seeking regulatory approval in the United States and Canada for veterinary prescriptive applications of Anipryl, first in dogs. The company is also identifying additional animal health product opportunities to become a multi-product animal health pharmaceutical company.
 -0- 9/3/92
 /CONTACT: David R. Stevens, president of Deprenyl Animal Health, Inc. 913-338-2120, or Irving L. Straus of Straus Corporate Communications, 212-768-2477, for Deprenyl Animal Health, Inc./
 (DAHI) CO: Deprenyl Animal Health, Inc. ST: Kansas IN: MTC SU:


PS-OS -- NY081 -- 6588 09/03/92 16:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 3, 1992
Words:434
Previous Article:BLUE LAKE GAS STORAGE COMPANY DECLARES OPEN SEASON
Next Article:DIGICON INC. ANNOUNCES YEAR END RESULTS
Topics:


Related Articles
DEPRENYL ANIMAL HEALTH REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL (L-DEPRENYL) FOR CUSHING'S DISEASE IN DOGS
DEPRENYL ANIMAL HEALTH, INC. REPORTS RESULTS OF OPERATIONS FOR THREE MONTHS ENDED SEPT. 30, 1992
DEPRENYL ANIMAL HEALTH, INC. REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL FOR TREATING COGNITIVE DYSFUNCTION (DEMENTIA) IN PET DOGS
DEPRENYL ANIMAL HEALTH, INC. REPORTS ON PHOENIX SCIENTIFIC, INC.
DEPRENYL ANIMAL HEALTH INC. SECURES ADDITIONAL FUNDING FROM DEPRENYL RESEARCH; DRL COMMITS $2.5 MILLION TO FUND DAHI OPERATIONS THROUGH 1995
DEPRENYL ANIMAL HEALTH INC. ANNOUNCES CONCLUSION OF PHASE II AND PIVOTAL CLINICAL TRIALS EVALUATING ANIPRYL(R) IN CANINE CUSHING'S DISEASE
DEPRENYL ANIMAL HEALTH INC. ACHIEVES FIRST EUROPEAN PATENT AND FIFTH U.S. PATENT FOR ANIPRYL(R) THERAPY
DEPRENYL ANIMAL HEALTH INC. REPORTS RESULTS OF OPERATIONS FOR THREE MONTHS ENDED MARCH 31, 1995
DEPRENYL ANIMAL HEALTH, INC. FILES PHASE III EQUIVALENT CLINICAL TRIAL REPORT WITH THE U.S. FDA
Aniprylr Available in Additional Dosages in Canada Shareholders to Vote on DRAXIS Exchange Offer for DAHI Shares

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters